Michiko Nonogi
Tokushima, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Sofosbuvir/Velpatasvir in Chronic Hepatitis C, Compensated and Decompensated Cirrhosis, and Retreatment Settings.
Journal: Internal medicine (Tokyo, Japan)
Published: January 04, 2026
Effect of Direct-Acting Antivirals on Prognosis in Older Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma After Curative Therapy: A Retrospective Study by the Red Cross Liver Study Group in Japan.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: August 11, 2025
Effect of Pemafibrate on Metabolic Dysfunction-Associated Steatotic Liver Disease: A Nationwide Multicenter Study.
Journal: JGH open : an open access journal of gastroenterology and hepatology
Published: July 17, 2025
Pemafibrate improves liver biochemistry and GLOBE scores in patients with primary biliary cholangitis: Nationwide, multicenter study by the Japanese Red Cross Liver Study Group.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: October 07, 2024
Effect of Proteinuria Before Lenvatinib Administration on Treatment Response After Atezolizumab Bevacizumab Combination Therapy.
Journal: JGH open : an open access journal of gastroenterology and hepatology
Published: August 13, 2024
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma.
Journal: Investigational new drugs
Published: July 17, 2024
Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection who had received direct-acting antiviral therapy.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: June 23, 2024
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group.
Journal: Investigational new drugs
Published: January 14, 2023
Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Journal: Investigational new drugs
Published: August 12, 2022
Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: June 02, 2022
Showing 1-11 of 11
Last Updated: 09/26/2026